skip to main content

Genitourinary symptoms associated with menopause during aromatase inhibitor therapy — DFSRH MCQ

Instant feedback + full explanation. One question, done properly.

EasyDyspareuniaGenitourinary symptoms associated with menopause during aromatase inhibitor therapyDFSRH

A 59-year-old woman presents with 9 months of vaginal dryness and superficial dyspareunia on penetration. She has no deep pelvic pain, abnormal discharge, postcoital bleeding or urinary symptoms. Examination shows diffuse pallor, thinning and loss of vaginal rugae, without a focal vulval lesion, ulceration, discharge or pelvic tenderness. She previously received surgery and radiotherapy for oestrogen receptor-positive breast cancer and is currently taking anastrozole as adjuvant therapy. Correct use of vaginal moisturiser and lubricant for 12 weeks has produced insufficient improvement, and the symptoms are affecting her relationship. Which is the most appropriate next management?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: E — Discuss further treatment options jointly with her breast cancer specialist

Explanation lettering: D = shown as A · E = shown as B · B = shown as D · A = shown as E

The superficial penetration pain, dryness and diffuse atrophic vaginal changes indicate genitourinary symptoms associated with menopause. The absence of discharge, pelvic tenderness, bleeding, ulceration or a focal lesion makes infection, deep pelvic pathology and vulval neoplasia less likely. NICE recommends non-hormonal moisturisers or lubricants initially for people with a personal history of breast cancer. When symptoms continue despite these measures in someone currently receiving an adjuvant aromatase inhibitor, clinicians should work with a breast cancer specialist to identify further treatment options. This permits individualised consideration of recurrence risk, endocrine therapy and local hormonal treatment. B is a credible next treatment for persistent symptoms after breast cancer, but it should not be initiated independently while she is taking an aromatase inhibitor. Some vaginal oestrogen is absorbed systemically, and its effect on recurrence risk remains uncertain. C is an option in people without this complicating history when vaginal oestrogen or non-hormonal treatments are ineffective or not tolerated; it should not replace specialist discussion here. D creates unnecessary systemic oestrogen exposure for isolated genitourinary symptoms in a woman with previous oestrogen receptor-positive cancer. E would be appropriate if examination showed a persistent focal lesion, ulceration or architectural abnormality, none of which is present.

Reference: Menopause: identification and management (NG23) — Recommendations (Recommendations updated November 2024; guideline last updated 15 April 2026) — https://www.nice.org.uk/guidance/ng23/chapter/Recommendations Menopause: identification and management (NG23) — Rationale and impact (November 2024) — https://www.nice.org.uk/guidance/ng23/chapter/Rationale-and-impact